catalpol has been researched along with regorafenib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Abd-Alhaseeb, MM; El-Hanboshy, SM; Helmy, MW | 1 |
1 other study(ies) available for catalpol and regorafenib
Article | Year |
---|---|
Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Iridoid Glucosides; Liver Neoplasms; NF-kappa B; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2021 |